Emerging Post-Immunotherapy Strategies in Renal Cell Carcinoma

Dr. Voss and Dr. Serzan discuss emerging treatment options for patients with advanced clear cell renal cell carcinoma (RCC) following progression on prior immunotherapy. Dr. Serzan reviews the phase 3 LITESPARK-011 study, which randomized patients with previously treated clear cell RCC to lenvatinib plus belzutifan or cabozantinib. He highlights the study's improvement in progression-free survival and objective response rate, as well as the longer duration of response observed with the combination. The experts also discuss the absence of a mature overall survival benefit to date and the potential role of efficacy endpoints beyond overall survival when evaluating later-line therapies. Dr. Serzan notes that, if approved and incorporated into treatment guidelines, lenvatinib plus belzutifan could be particularly relevant for patients who require meaningful tumor shrinkage after progression on immunotherapy. They also consider the combination's distinct toxicity profile, including anemia, hypoxia, and potential cardiovascular effects, emphasizing the importance of appropriate patient counseling, monitoring, and further clinical experience as this treatment approach evolves.